These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33183151)

  • 1. Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody.
    Boyles JS; Beidler CB; Strifler BA; Girard DS; Druzina Z; Durbin JD; Swearingen ML; Lee LN; Kikly K; Chintharlapalli S; Witcher DR
    MAbs; 2020; 12(1):1831880. PubMed ID: 33183151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels.
    Zhao X; Town JR; Li F; Zhang X; Cockcroft DW; Gordon JR
    J Immunol; 2009 Mar; 182(5):3213-22. PubMed ID: 19234219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.
    Zhao X; Li F; Town JR; Zhang X; Wang W; Gordon JR
    Int Immunopharmacol; 2007 Dec; 7(13):1723-31. PubMed ID: 17996682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.
    Addison CL; Daniel TO; Burdick MD; Liu H; Ehlert JE; Xue YY; Buechi L; Walz A; Richmond A; Strieter RM
    J Immunol; 2000 Nov; 165(9):5269-77. PubMed ID: 11046061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-ELR CXC chemokine encoded by human cytomegalovirus UL146 genotype 5 contains a C-terminal β-hairpin and induces neutrophil migration as a selective CXCR2 agonist.
    Berg C; Wedemeyer MJ; Melynis M; Schlimgen RR; Hansen LH; Våbenø J; Peterson FC; Volkman BF; Rosenkilde MM; Lüttichau HR
    PLoS Pathog; 2022 Mar; 18(3):e1010355. PubMed ID: 35271688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78.
    Wuyts A; Proost P; Lenaerts JP; Ben-Baruch A; Van Damme J; Wang JM
    Eur J Biochem; 1998 Jul; 255(1):67-73. PubMed ID: 9692902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2.
    Zaslaver A; Feniger-Barish R; Ben-Baruch A
    J Immunol; 2001 Jan; 166(2):1272-84. PubMed ID: 11145710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling.
    Feniger-Barish R; Belkin D; Zaslaver A; Gal S; Dori M; Ran M; Ben-Baruch A
    Blood; 2000 Mar; 95(5):1551-9. PubMed ID: 10688807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2.
    Wolf M; Delgado MB; Jones SA; Dewald B; Clark-Lewis I; Baggiolini M
    Eur J Immunol; 1998 Jan; 28(1):164-70. PubMed ID: 9485196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
    J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
    Busch-Petersen J
    Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8.
    Li F; Zhang X; Gordon JR
    Biochem Biophys Res Commun; 2002 May; 293(3):939-44. PubMed ID: 12051749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis.
    Mehrad B; Strieter RM; Moore TA; Tsai WC; Lira SA; Standiford TJ
    J Immunol; 1999 Dec; 163(11):6086-94. PubMed ID: 10570298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
    Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modes of regulation of cxc chemokine-induced internalization and recycling of human CXCR1 and CXCR2.
    Feniger-Barish R; Ran M; Zaslaver A; Ben-Baruch A
    Cytokine; 1999 Dec; 11(12):996-1009. PubMed ID: 10623425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer.
    Matsuo Y; Raimondo M; Woodward TA; Wallace MB; Gill KR; Tong Z; Burdick MD; Yang Z; Strieter RM; Hoffman RM; Guha S
    Int J Cancer; 2009 Sep; 125(5):1027-37. PubMed ID: 19431209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
    Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
    Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.